All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On 1 February 2019, tisagenlecleucel, a CAR T-cell therapy, was granted approval by the National Institute for Health and Care Excellence (NICE) for the treatment of adults, who did not previously respond to two or more treatments, with diffuse large B-cell lymphoma (DLBCL). This approval means tisagenlecleucel will be available on the National Health Service (NHS), with funding from the Cancer Drugs Fund (CDF).
Tisagenlecleucel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) large B-cell lymphomas.
The approval granted by NICE was based on the positive results obtained from the ongoing, pivotal, multicenter, phase II JULIET trial (NCT02445248) assessing the safety and efficacy of tisagenlecleucel, in patients with previously treated DLBCL. The phase II JULIET study demonstrated a median relapse-free survival rate of 64% and an overall survival rate of 43% at 18-months in patients with R/R DLBCL.
The prognosis for patients with DLBCL is generally poor with limited treatment options. The NICE approval of tisagenlecleucel provides the opportunity to transform the treatment of patients with R/R DLBCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox